Open labeled, multicenter phase I/II study evaluating the dose escalation/safety of cetuximab and oxaliplatin/ 5-FU [5-fluorouracil]/FA [folinic acid]/irinotecan as first-line treatment of metastatic colorectal cancer

Trial Profile

Open labeled, multicenter phase I/II study evaluating the dose escalation/safety of cetuximab and oxaliplatin/ 5-FU [5-fluorouracil]/FA [folinic acid]/irinotecan as first-line treatment of metastatic colorectal cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jan 2014

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Sep 2013 Planned number of patients changed from 34 to 21 as reported by ClinicalTrials.gov.
    • 26 Feb 2009 Actual patient number (21) added as reported by ClinicalTrials.gov.
    • 26 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top